Merit Medical Systems (Nasdaq:MMSI) announced today that it launched the Temno Elite soft tissue biopsy system in the U.S.
South Jordan, Utah-based Merit designed Temno Elite for use in various soft tissue locations. This includes the liver, lung, lymph nodes, kidney, and other soft tissue suspect lesions.
The single-use device complements a broader portfolio, the company said. The portfolio includes the TEMNO, Achieve and Tru-Cut device families.
Merit designed Temno Elite to retrieve superior samples, according to a news release. The Temno Elite Total Core biopsy technology provides samples 72% larger than competitor side-notch, semi-automatic devices. It features Sample Assist technology to simplify tissue removal as well.
Sample Assist allows clinicians to retrieve full samples with just the slide of a button. Additionally, it includes an optional, valved coaxial introducer. This enhances patient safety by reducing the risk of air entry and fluid leakage, particularly important during lung biopsy.
Merit produces ‘excellent’ sample quality with Temno Elite
Dr. Stuart Aronson diagnostic radiology specialist at Texas Health Harris Methodist Hospital in Fort Worth, Texas, called the system’s sample quality “excellent.” He said the cores come in “noticeably and consistently” larger than other devices. Meanwhile, he noted that the introducer reduces procedural steps, blood leakage and the risk of pneumothorax and air embolism.
“Merit is committed to helping physicians provide the best care possible for their patients—and this includes the crucial step of accurate diagnosis,” said Fred P. Lampropoulos, Merit Medical chair and CEO. “The Temno Elite is the latest innovation in our portfolio of soft tissue biopsy devices, and it highlights Merit’s ability to understand clinician and patient needs and innovate and deliver technologies that advance patient care.”